Analysts set CNY 280.14 target for Mindray stock
Published on 10/12/2026 at 09:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Mindray reported RMB 17.747 billion in first-half 2026 revenue, up 6.00 percent year over year.
- International revenue rose 13.67 percent to RMB 9.471 billion in the first half of 2026.
- Mindray stock was last at CNY 166.00 on October 12, 2026, with a CNY 201.3 billion market value.
- Eulerpool listed a CNY 280.14 analyst target and 30 Buy recommendations among 32 analysts.
Mindray's stock has a CNY 280.14 analyst target, while the company reported RMB 17.747 billion in first-half 2026 revenue, according to Eulerpool on October 4, 2026. The target sits above the CNY 166.00 home-market quote, giving the valuation debate a clear numerical anchor.
First-half revenue keeps growing
According to min.news on October 10, 2026, Mindray generated RMB 17.747 billion of operating revenue in the first half of 2026, a 6.00 percent year-over-year increase. Net profit attributable to the parent company reached RMB 4.797 billion, while operating cash flow stood at RMB 4.877 billion.
The second quarter supplied the sharper growth signal. Revenue reached RMB 9.395 billion, up 10.45 percent year over year, and net profit attributable to the parent company reached RMB 2.467 billion, an increase of 1.10 percent.
International sales lead the mix
International revenue rose 13.67 percent to RMB 9.471 billion in the first half of 2026 and represented 53.37 percent of total revenue. That comparison matters because domestic revenue stood at RMB 8.276 billion, leaving overseas operations as the larger contributor for the period.
Emerging businesses produced RMB 3.110 billion of first-half revenue, up 19.59 percent year over year. In-vitro diagnostics generated RMB 6.865 billion, an increase of 9.58 percent, while research and development investment reached RMB 1.779 billion, equal to 10.02 percent of revenue.
What does the target imply?
Eulerpool's overview listed 30 Buy recommendations among 32 analysts and an average target of CNY 280.14. Against the CNY 166.00 quote, that target is 68.76 percent above the price, although the target represents analyst expectations rather than a company forecast.
Mindray was last at CNY 166.00 on the Shenzhen Stock Exchange at 3:04 p.m. China Standard Time on October 12, 2026. Its market capitalization was CNY 201.3 billion, and the 52-week range was CNY 130.66 to CNY 239.99 on the same date.
Mindray stock facts
- Company: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- ISIN: CNE100003G67
- Ticker: 300760.SZ
- Primary exchange: Shenzhen Stock Exchange
- Price Shenzhen Stock Exchange (as of October 12, 2026, 3:04 p.m. China Standard Time): CNY 166.00
- Market capitalization: CNY 201.3 billion (as of October 12, 2026)
- 52-week range: CNY 130.66-CNY 239.99 (as of October 12, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report Shanghai Composite.
